Mosunetuzumab-axgb

{
  "id": "MLC-T-ONC-015285",
  "term": "Mosunetuzumab-axgb",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.",
  "synonyms": [
    "mosunetuzumab",
    "CD20/CD3 BiMAb BTCT4465A",
    "anti-CD20 x anti-CD3 bispecific monoclonal antibody BTCT4465A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mosunetuzumab-axgb/"
}